OncoMed Pharmaceuticals, Inc. Updates Phase 1b Data for Demcizumab With Pemetrexed and Carboplatin in Patients With First-Line Stage IIIb/IV Non-Small Cell Lung Cancer at the American Association for Cancer Research-National Cancer Institute-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 19-23, 2013
10/21/2013 9:26:53 AM
REDWOOD CITY, Calif., Oct. 20, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported updated Phase 1b data for demcizumab (OMP-21M18, Anti-DLL4), a monoclonal antibody targeting the Notch pathway, with carboplatin and pemetrexed in patients with first-line, stage IIIb/IV non-small cell lung cancer (NSCLC). The update was presented at a poster session at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 19-23, 2013, at the Hynes Convention Center in Boston, MA. Based on the data, OncoMed is planning to initiate a randomized Phase 2 trial of demcizumab with carboplatin and pemetrexed in first-line NSCLC in 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by